Drugmakers Increasingly Using Basket Trials to Gain Precision Medicine Insights, ASCO Studies Show | GenomeWeb

CHICAGO – Drug companies are increasingly utilizing basket trials to efficiently gain insights into small, molecularly defined subpopulations of patients who might benefit from their investigational and marketed drugs.

As industry invests in such trials, however, it remains to be see whether the US Food and Drug Administration will accept data from these studies for registration trials and whether payors will reimburse for next-generation sequencing conducted as part of such investigations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.